Horizon Therapeutics PLC
Change company Symbol lookup
Select an option...
HZNP Horizon Therapeutics PLC
KGSPF Kingspan Group PLC
RZA Reinsurance Group of America Inc
MUSA Murphy Usa Inc
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
Go

Health Care : Biotechnology | Mid Cap Growth
Based in Ireland
Company profile

Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).

Closing Price
$78.28
Day's Change
0.75 (0.97%)
Bid
--
Ask
--
B/A Size
--
Day's High
78.45
Day's Low
77.56
Volume
(Light)
Volume:
534,719

10-day average volume:
1,658,583
534,719

HZNP's position in the Biotechnology industry

Industry PeersHZNPGILD

Summary

Company ProfileHorizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human...
Go to GILD summary
52-Week Change

VS. INDUSTRY
-25.36%
23.11%
Market Cap

VS. INDUSTRY
$17.7B
$108.2B
Beta

VS. INDUSTRY
1.1
0.5
Dividend Yield

VS. INDUSTRY
--
3.39%
P/E (TTM, GAAP)

VS. INDUSTRY
24.18x
32.62x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$3.8B
$27.1B
Profit Margin

VS. INDUSTRY
20.06%
12.19%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
-13.08%
Revenue Growth (TTM)

VS. INDUSTRY
49.14%
-1.26%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.